152 related articles for article (PubMed ID: 37965898)
21. A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach.
Haig M; Main C; Chávez D; Kanavos P
Value Health; 2023 Oct; 26(10):1474-1484. PubMed ID: 37385445
[TBL] [Abstract][Full Text] [Related]
22. Application of a health technology assessment framework to digital health technologies that manage chronic disease: a systematic review.
von Huben A; Howell M; Carrello J; Norris S; Wortley S; Ritchie A; Howard K
Int J Technol Assess Health Care; 2021 Dec; 38(1):e9. PubMed ID: 34924061
[TBL] [Abstract][Full Text] [Related]
23. Digital Health Technology for Real-World Clinical Outcome Measurement Using Patient-Generated Data: Systematic Scoping Review.
Pyper E; McKeown S; Hartmann-Boyce J; Powell J
J Med Internet Res; 2023 Oct; 25():e46992. PubMed ID: 37819698
[TBL] [Abstract][Full Text] [Related]
24. The role of economic, educational and social resources in supporting the use of digital health technologies by people with T2D: a qualitative study.
Turnbull S; Lucas PJ; Hay AD; Cabral C
BMC Public Health; 2021 Feb; 21(1):293. PubMed ID: 33546661
[TBL] [Abstract][Full Text] [Related]
25. Data-driven digital health technologies in the remote clinical care of diabetic foot ulcers: a scoping review.
Lazarus J; Cioroianu I; Ehrhardt B; Gurevich D; Kreusser L; Metcalfe B; Nishtala P; Preatoni E; Sharp TH
Front Clin Diabetes Healthc; 2023; 4():1212182. PubMed ID: 37727285
[TBL] [Abstract][Full Text] [Related]
26. HCI-modelling for improving the clinical usability of digital health technologies.
Paton C; Borycki EM; Warren J; Kushniruk AW; English M
Methods; 2024 Jul; 227():60-77. PubMed ID: 38729456
[TBL] [Abstract][Full Text] [Related]
27. Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms.
Marra C; Stern AD
Clin Pharmacol Ther; 2024 May; 115(5):988-992. PubMed ID: 38308421
[TBL] [Abstract][Full Text] [Related]
28. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Process Evaluation of Using Digital Health Technologies in Pharmaceutical Care in Low- and Middle-Income Countries: A Systematic Review of Quantitative and Qualitative Studies.
Alfian SD; Insani WN; Puspitasari IM; Wawruch M; Abdulah R
Telemed J E Health; 2023 Sep; 29(9):1289-1303. PubMed ID: 36749170
[No Abstract] [Full Text] [Related]
30. Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model.
Crawford F; Chappell FM; Lewsey J; Riley R; Hawkins N; Nicolson D; Heggie R; Smith M; Horne M; Amanna A; Martin A; Gupta S; Gray K; Weller D; Brittenden J; Leese G
Health Technol Assess; 2020 Nov; 24(62):1-198. PubMed ID: 33236718
[TBL] [Abstract][Full Text] [Related]
31. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
32. Implementation of a new Digi-HTA process for digital health technologies in Finland.
Haverinen J; Turpeinen M; Falkenbach P; Reponen J
Int J Technol Assess Health Care; 2022 Aug; 38(1):e68. PubMed ID: 35983625
[TBL] [Abstract][Full Text] [Related]
33. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
Thokala P; Carlson JJ; Drummond M
J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
[TBL] [Abstract][Full Text] [Related]
34. Selecting digital health technologies for validation and piloting by healthcare providers: a decision-making perspective from ontario.
Chahal A; Rudnick A
Int J Technol Assess Health Care; 2019 Jan; 35(1):1-4. PubMed ID: 30714547
[TBL] [Abstract][Full Text] [Related]
35. Facilitators and barriers of digital health technologies implementation in hospital settings in lower-income and middle-income countries since the COVID-19 pandemic: a scoping review protocol.
Yew SQ; Trivedi D; Adanan NIH; Chew BH
BMJ Open; 2024 Jan; 14(1):e078508. PubMed ID: 38296272
[TBL] [Abstract][Full Text] [Related]
36. Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals.
Dóczy V; Wernerné Sódar B; Hölgyesi Á; Merész G; Gaál P
Int J Technol Assess Health Care; 2022 Jul; 38(1):e58. PubMed ID: 35819299
[TBL] [Abstract][Full Text] [Related]
37. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
38. The Promises and Pitfalls of Digital Technology in Its Application to Alcohol Treatment.
Muench F
Alcohol Res; 2014; 36(1):131-42. PubMed ID: 26259008
[TBL] [Abstract][Full Text] [Related]
39. Mental health professionals views and the impact of COVID-19 pandemic on implementing digital mental health in China: A nationwide survey study.
Zhang X; Lewis S; Chen X; Berry N; Bucci S
Internet Interv; 2022 Dec; 30():100576. PubMed ID: 36185346
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
